The supplemental value of mammographic screening over breast MRI alone in BRCA2 mutation carriers

ConclusionsIn BRCA2 mutation carriers younger than 40  years, the benefit of mammographic screening over MRI was very small. In carriers of 50 years and older, mammographic screening contributed significantly. Hence, we propose to postpone mammographic screening in BRCA2 mutation carriers to at least age 40.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research